Pharmacyclics Completes $52.4 Million Registered Direct Offering
June 17, 2010
Olshan’s client Pharmacyclics, Inc., a NASDAQ-listed clinical-stage biopharmaceutical company, announced that it completed a $52.4 million registered direct offering of its common stock. Olshan represented Pharmacyclics in this matter.